These findings suggested that the clinical stroke therapy of rt-PA should combine with the pharmacological approach that normalized the HDAC6 activity which the rt-PA could help to restore the blood supply during the acute phase of stroke challenge and the HDAC6 modulators provide chronic therapeutic benefits that promote functional recovery of the brain afterwards. The gene discussed is HDAC6; the disease is stroke disorder.